NEXI-300

NEXI-300 is a preclinical-stage drug candidate being developed by NexImmune for the treatment of infectious diseases. It utilizes NexImmune's proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform, which is designed as an injectable modality. The AIM nanoparticles function as synthetic dendritic cells that direct specific T cell-mediated immune responses. These nanoparticles are engineered to activate, tolerize, or delete antigen-specific populations of T cells and are intended for direct injection or infusion to engage T cells inside the body. While the specific molecular targets for NEXI-300 have not been publicly disclosed, the platform aims to provide a targeted approach to managing infectious diseases by modulating the host's cellular immune response.